The latest price target for IDEAYA Biosciences (NASDAQ:IDYA) was reported by RBC Capital on January 15, 2025. The analyst firm set a price target for $61.00 expecting IDYA to rise to within 12 months (a possible 161.97% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for IDEAYA Biosciences (NASDAQ:IDYA) was provided by RBC Capital, and IDEAYA Biosciences reiterated their outperform rating.

The last upgrade for IDEAYA Biosciences Inc happened on April 24, 2023 when Stifel raised their price target to $24. Stifel previously had a hold for IDEAYA Biosciences Inc.

The last downgrade for IDEAYA Biosciences Inc happened on November 5, 2024 when Leerink Partners changed their price target from $41 to $27 for IDEAYA Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEAYA Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEAYA Biosciences was filed on January 15, 2025 so you should expect the next rating to be made available sometime around January 15, 2026.

While ratings are subjective and will change, the latest IDEAYA Biosciences (IDYA) rating was a reiterated with a price target of $61.00 to $61.00. The current price IDEAYA Biosciences (IDYA) is trading at is $23.29, which is out of the analyst’s predicted range.